Difference between revisions of "Part:BBa K3582026:Design"

 
(→‎References)
Line 21: Line 21:
  
 
===References===
 
===References===
 +
*1] Gould, A., Ji, Y., Aboye, T. L., & Camarero, J. A. (2011, December). Cyclotides, a novel ultrastable polypeptide scaffold for drug discovery. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3330703/
 +
*2] DJ;, P. A. (n.d.). Cyclotides as grafting frameworks for protein engineering and drug design applications. Retrieved from https://pubmed.ncbi.nlm.nih.gov/23893608/
 +
*3] Camarero, J. A., & Campbell, M. J. (2019, April 19). The Potential of the Cyclotide Scaffold for Drug Development. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6631875/

Revision as of 16:13, 20 October 2020


Inhibitory sequence 1 of PfEMP1 - ICAM1 interaction grafted into a cyclotide


Assembly Compatibility:
  • 10
    COMPATIBLE WITH RFC[10]
  • 12
    COMPATIBLE WITH RFC[12]
  • 21
    COMPATIBLE WITH RFC[21]
  • 23
    COMPATIBLE WITH RFC[23]
  • 25
    INCOMPATIBLE WITH RFC[25]
    Illegal AgeI site found at 112
  • 1000
    INCOMPATIBLE WITH RFC[1000]
    Illegal BsaI site found at 143
    Illegal BsaI.rc site found at 109


Design Notes

  • 1] RFC10 criteria satisfied
  • 2] Strep Ⅱ tag gene inserted in loop 3
  • 3] Codon optimized with E-coli K-12 strain
  • 4] Inhibitor 1 grafted in loop 6
  • 5] C and N intein added for circularization



Source

Reverse translation of amino acid sequence

References